Trial reportInternational journal of chronic obstructive pulmonary disease2020
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.
Trial report in International journal of chronic obstructive pulmonary disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02058459 (A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment With the Holaira™ Lung Denervation System in Patients With Moderate to Severe COPD.), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment With the Holaira™ Lung Denervation System in Patients With Moderate to Severe COPD.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).American journal of respiratory and critical care medicine · 2025Trial
- The Rise and Fall of Interventional Pulmonology Procedures: Lessons in Innovation, Evidence, and Abandonment.Diagnostics (Basel, Switzerland) · 2026Review
- Bronchial Thermoplasty Induced Changes in Blood Transcriptome Profile of Patients with Severe Asthma.International journal of molecular sciences · 2026Article
- Autonomic nervous system dysfunction in chronic obstructive pulmonary disease: mechanistic insights and therapeutic implications.Annals of medicine · 2025Review
- Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs.Journal of clinical medicine · 2025Review
- Review
- Bronchoscopic Management of COPD and Advances in Therapy.Life (Basel, Switzerland) · 2023Review
- Modern Bronchoscopic Treatment Options for Patients with Chronic Bronchitis.Journal of clinical medicine · 2023Article
- Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation: A Report From the National Heart, Lung, and Blood Institute and the National Institutes of Health Office of the Director Workshop.JACC. Basic to translational science · 2022Review
- ERS International Virtual Congress 2021: Highlights from the Turkish Thoracic Society Early Career Members.Turkish thoracic journal · 2022Article
- ERS International Congress 2020: highlights from the Clinical Techniques, Imaging and Endoscopy assembly.ERJ open research · 2021Review
- ERS International Congress, Madrid, 2019: highlights from the Clinical Techniques, Imaging and Endoscopy Assembly.ERJ open research · 2020Article
- ERS International Congress 2019: highlights from Best Abstract awardees.Breathe (Sheffield, England) · 2019Article
- Airway Innervation and Plasticity in Asthma.Physiology (Bethesda, Md.) · 2019Review
- European Respiratory Society International Congress, Paris, 2018: highlights from the Clinical Assembly.ERJ open research · 2019Review
- Preview of highlighted presentations from the European Respiratory Society' clinical assembly.Journal of thoracic disease · 2018Article
- [Highlights of the 58th Congress of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)].Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 19 institutions in 6 countries.
Funding
Abstract
Purpose: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to reduce clinical consequences of cholinergic hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, symptomatic COPD two years post randomization. Patients and Methods: TLD was performed in COPD patients (FEV Results: Eighty-two subjects (FEV Conclusion: In a randomized trial, TLD demonstrated a durable effect of significantly lower risk of severe AECOPD over 2 years. Further, lung function and quality of life remained stable following TLD. Clinical Trial Registration: NCT02058459.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.